AFP and Cirrhosis: Because most of the evidence-based studies showed a benefit of the combination of ultrasonography and alpha-fetoprotein (AFP) in improving overall survival, the current American Association for the Study of Liver Diseases Guideline recommends surveillance for patients with cirrhosis by liver ultrasonography with or without AFP every 6 months [12].